Publications
Clinical Publications
2024
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Seval Beykan Schürrle et al.
EJNMMI 2024; 2024 Mar 26. doi: 10.1007/s00259-024-06682-1
CITADEL-123. TRIAL IN PROGRESS A Phase I clinical trial to assess the activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor (123I-ATT001) directly administered in subjects with relapsed glioblastoma (rGBM).
Paul Mulholland et al.
NMN Symposium: Precision Medicine 2024
2023
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
Wild D et al.
EJNMMI 2023; 2023 Sep 18. doi: 10.1007/s00259-023-06383-1
2022
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Virgolini I et al.
J Nucl Med 2022; 63: 376-383.
2021
A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in pts with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial.
Miller CG et al.
EJNMMI Res 2021; 11: 84.
Safety and Effectiveness of 177Lu-Satoreotide Tetraxetan in Patients with Progressive Neuroendocrine Tumors (NETs):
Interim Analysis of a Phase I/II Study.
Grønbæk H et al.
NANETS 2021, C-31: Poster 411.
2020
Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR
Young et al.
Neurooncol Adv 2020; 15:2.
Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer
Schöder et al.
Clin Cancer Res (2020) 26 (13): 3110–3116.
2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.
Reidy-Lagunes D et al.
Clin Cancer Res 2019; 25(23):6939-6947.
2018
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.
Nicolas GP et al.
J Nucl Med 2018; 59: 909-914.
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
Nicolas GP et al.
J Nucl Med 2018; 59: 915-921.
2014
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study.
Wild D et al.
J Nucl Med 2014; 55(8): 1248-1252.
Non-clinical Publications
2025
[225Ac]-SSO110 as next-generation SSTR2 targeting radiopharmaceutical for small cell lung cancer and other aggressive neuroendocrine neoplasms.
Jaekel A et al.
ACCR Annual Meeting 2025
2024
[225Ac]Ac-SSO110 and [177Lu]Lu-SSO110 demonstrate significantly better efficacy than [225Ac]Ac-DOTA-TATE in the treatment of SSTR2-positive tumor xenografts
Jaekel A et al.
SNMMI Annual Meeting 2024
Discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display
Jaekel A et al.
AACR 2024
2021
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE.
Mansi R et al.
Pharmaceuticals 2021; 14: 1265.
PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Wilson T et al.
Mol Pharm., 2021; 18: 3418-3428
2020
Targeted Brain Tumor Radiotherapy Using an Auger Emitter.
Pirovano G et al.
Clin Cancer Res, 2020; 26: 2871-2881.
2019
Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors.
Mansi R et al.
J Labelled Compounds RPs 2019; 62(10): 635-645.
2017
Somatostatin Receptor Antagonists for Imaging and Therapy.
Fani M et al.
J Nucl Med 2017; 58: 61S-66S.
2016
Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled SSTR Agonist and Antagonist in Preclinical Models.
Dalm SU et al.
J Nucl Med 2016; 57: 260-265.
2011
PET of Somatostatin Receptor-Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chellate Makes the Difference.
Fani M et al.
J Nucl Med 2011; 52: 1110-1118.
2008
Design and in vitro Characterization of Highly Sst2-selective Somatostatin Antagonists Suitable for Radio-Targeting.
Cescato R et al.
J Med Chem 2008; 51-13:4030-4037.
2006
Radiolabeled somatostatin antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
Ginj M et al.
PNAS 2006; 103(44): 16436-16441.
© Ariceum Therapeutics
